ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.9 5年インパクトファクター: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 37, 2020 巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2015011592
pages 247-275

Polymeric Drug-Delivery Systems: Role in P-gp Efflux System Inhibition

Preeti Gupta
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Tarun Garg
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
M. Tanmay
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Saahil Arora
Department of Pharmaceutics, ISF College of Pharmacy, Moga (Punjab), India 09501223252(M)

要約

Permeability glycoprotein (P-gp), a multispecific drug transporter belonging to the multidrug resistance (MDR) gene subfamily, is mainly responsible for efflux of diffused intracellular drugs, resulting in poor drug bioavailability. P-gp is overexpressed in the blood-brain barrier, gastrointestinal tract (GIT), kidney, liver, pancreas, and cancerous cells, leading to multidrug resistance and failure of therapy. Because P-gp is transported into cells by way of receptor-mediated endocytosis (in contrast to diffusion for free drug), polymeric efflux pump modulators can have a major role in efficient drug delivery. Various polymer drug conjugates that have been proven to provide potential treatments in MDR cases are reviewed here, with an emphasis on the role of the P-gp efflux pump, bioavailability, and the mechanism of inhibition of the P-gp transporter by various polymers and delivery systems. This review also highlights the potential of specific polymer drug conjugates to act as P-gp efflux pump inhibitors to provide enhanced bioavailability and therapeutic efficacy.


Articles with similar content:

Polymeric Lipid Hybrid Nanoparticles: Properties and Therapeutic Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 6
Kesrin Amra, Munira Momin, Chintan Bhavsar, Abdelwahab Omri, Cyril Jose
Drug Targeting by Surface Cationization
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.17, 2000, issue 5
Susan Moody Haupt, Tareq Taha Jubeh, Abraham Rubinstein, Sigal Blau
Peptide and Protein Delivery Using New Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Ashish Jain, Satish Shilpi, Pooja Hurkat, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain
Gene Delivery Using Lipoplexes and Polyplexes: Principles, Limitations and Solutions
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 1
Amir Roointan, Najmeh Farahani, Esmat Safdarian, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
Colorectal Cancer Management by Herbal Drug-Based Nanocarriers: An Overview
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.37, 2020, issue 1
Sujata P. Sawarkar, Krishna Baxi, Vritika Kulwal, Lokesh Kumar Bhatt